Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
The Delcath Systems Inc (DCTH) news page on Stock Titan aggregates company announcements, clinical updates, and financial disclosures for this interventional oncology business focused on primary and metastatic liver cancers. Delcath’s communications frequently highlight developments related to its proprietary hepatic delivery technologies, HEPZATO KIT and the CHEMOSAT Hepatic Delivery System for Melphalan, which are used in percutaneous hepatic perfusion (PHP) procedures.
Investors and observers can use this news feed to follow earnings reports and financial updates, including quarterly and preliminary revenue results, product revenue from HEPZATO KIT in the United States and CHEMOSAT in Europe, gross margin commentary, and discussions of non-GAAP measures such as adjusted EBITDA. The company also issues releases on capital allocation and corporate actions, such as authorization of share repurchase programs and equity inducement grants under stock incentive plans.
A significant portion of Delcath’s news flow centers on clinical and scientific developments. Recent announcements describe subgroup analyses from the Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in unresectable metastatic uveal melanoma, the Phase 2 CHOPIN trial evaluating CHEMOSAT with ipilimumab and nivolumab, real-world evidence from retrospective analyses of metastatic uveal melanoma patients, and a 10-year single-center experience with CHEMOSAT in liver-dominant disease. The company also highlights expert narrative reviews discussing PHP with melphalan using HEPZATO KIT, including patient selection, technique, and outcomes.
Additional updates include participation in investor conferences and scheduling of earnings calls, providing context for how Delcath communicates with the capital markets. For users tracking DCTH, this page offers a centralized view of regulatory, clinical, and financial news that shapes the company’s progress in liver-directed oncology therapies. Bookmark this feed to monitor new data releases, product-related publications, and ongoing disclosures from Delcath Systems Inc.
Delcath Systems (Nasdaq: DCTH) reported Q1 2026 results and provided 2026 guidance. Total revenue was $25.0M (HEPZATO $23.3M; CHEMOSAT $1.7M). Gross margin was 85%. Net loss was $1.1M and adjusted EBITDA was $3.4M. Cash and investments totaled $89.3M as of March 31, 2026.
The company reaffirmed 2026 revenue guidance of at least $100M, projected gross margins of 84–87%, and positive adjusted EBITDA. Business highlights include ~36% HEPZATO volume growth YoY and 29 active centers.
Delcath Systems (Nasdaq: DCTH) announced presentation of new retrospective data on percutaneous hepatic perfusion with melphalan (M-PHP) for liver-dominant metastatic breast cancer at ESMO Breast Cancer Congress 2026 on May 7, 2026.
Presentation: e-poster at 13:15 local time, Abstract #574eP, presenter Cornelia Lieselotte Angelika Dewald, MD (Hannover Medical School). The analysis evaluates safety and feasibility of M-PHP using the CHEMOSAT Hepatic Delivery System.
Delcath Systems (Nasdaq: DCTH) will host a conference call on May 7, 2026 at 8:30 AM Eastern Time to discuss results for the first quarter ended March 31, 2026. Participants should dial in 5–10 minutes early or join the live webcast. A replay will be archived on the company website.
Dial-in numbers: Toll Free 1-800-717-1738; International 1-646-307-1865. Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1757946&tp_key=463dd4d428.
Delcath Systems (Nasdaq: DCTH) announced inclusion of its CHEMOSAT Hepatic Delivery System for Melphalan (M-PHP) as a recommended liver-directed regional therapy in the April 2026 ESMO–EURACAN clinical practice guideline for uveal melanoma. The guideline also cites two Phase 3 trials showing improved hepatic and overall progression-free survival and lists M-PHP first among regional options for multifocal liver-only metastases.
The guideline assigns an ESMO-Magnitude of Clinical Benefit Scale score of 3 for select patients and recognizes HEPZATO KIT as a Category 2A option for hepatic-dominant metastatic uveal melanoma.
Delcath Systems (NASDAQ:DCTH) will participate in the Society of Interventional Radiology 2026 Annual Scientific Meeting in Toronto, April 11–15, 2026.
The company’s Hepatic Delivery System for percutaneous hepatic perfusion (PHP) appears in three presentations on April 13 and April 15, 2026, featuring physicians from Massachusetts General Hospital, Thomas Jefferson University, and University of Wisconsin. Abstracts are available on the company website under Scientific Meetings.
Delcath Systems (Nasdaq: DCTH) announced publication of the CHOPIN randomized Phase 2 trial in The Lancet Oncology showing improved outcomes when combining percutaneous hepatic perfusion (PHP) with ipilimumab and nivolumab in metastatic uveal melanoma.
Key results: 1-year PFS 54.7% vs 15.8% (HR 0.34; p=0.0002), median PFS 12.8 vs 8.3 months, median OS 23.1 vs 19.6 months (HR 0.39; p=0.0065), ORR 76.3% vs 39.5%. Higher grade ≥3 toxicity in the combination arm (82% vs 41%) and one treatment-related death were reported.
Delcath (Nasdaq: DCTH) reported strong 2025 results with $85.2M revenue and $2.7M GAAP net income for the full year, plus $25.1M adjusted EBITDA. Fourth-quarter revenue was $20.7M and gross margins were 85%–86%. The company ended 2025 with $91.0M cash and no debt, repurchased 628,572 shares for $6.0M, and guided 2026 revenue to at least $100M with 84%–87% gross margins.
Clinical and commercial momentum included ~140% HEPZATO procedure-volume growth, 28 active centers, and published CHOPIN and FOCUS study results supporting adoption.
Delcath Systems (Nasdaq: DCTH) will hold a conference call on February 26, 2026 at 8:30 AM Eastern Time to discuss fourth quarter and full year results for the period ended December 31, 2025.
Participants can join by toll-free or international dial-in or via webcast; a replay will be archived on the company website.
Delcath Systems (Nasdaq: DCTH) announced management will attend the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on January 27, 2026, at the Cliff Lodge in Snowbird, Utah.
The appearance signals management engagement with investors and industry peers; no financial results, presentations, or new regulatory updates were announced.
Delcath Systems (Nasdaq: DCTH) granted equity inducements under Nasdaq Listing Rule 5635(c)(4) to four new employees who began work in November or December 2025. The company issued 36,250 Restricted Stock Units (RSUs) under its 2023 Inducement Plan, with grants dated January 2, 2026. Vesting: one-third on the first anniversary of the grant and the remaining two-thirds in equal annual installments over the next two years, subject to continued employment on each vesting date. The awards were approved by the Compensation Committee and issued pursuant to the Plan and Nasdaq rules.